What is Vibra Healthcare’s role under the MindMaze Therapeutics partnership?

Vibra Healthcare will use its national relationships and operational credibility to connect MindMaze Therapeutics with providers investing in advanced neurorehabilitation capabilities. The partnership follows a previously announced term sheet.

What experience underpins the MindMaze Therapeutics and Vibra Healthcare agreement?

The commercial model is based on Vibra Healthcare’s two-year, multi-site deployment of the MindMaze Therapeutics platform across five inpatient rehabilitation centres. The announcement says this deployment demonstrated that guideline-recommended high-dose, high-intensity therapy could be operationalised at scale without increasing staffing burden.

What does MindMaze Therapeutics expect from the Vibra Healthcare partnership?

MindMaze Therapeutics expects the Vibra Healthcare partnership to be a key driver of new U.S. health system customer acquisition in the second half of 2026 and beyond. This is the company’s stated expectation.

What benefits does the MindMaze Therapeutics platform offer adopting providers?

The announcement says providers adopting the platform gain a scalable solution that enables clinicians to treat more patients at a higher level of care with the same resources. It also says the platform supports shorter inpatient lengths of stay, improves community discharge rates and delivers consistent therapy intensity across the full continuum of care.

What did MindMaze Therapeutics CEO Zach Henderson say about the Vibra Healthcare agreement?

Zach Henderson said the next phase of the collaboration was a significant step in MindMaze Therapeutics’ U.S. commercial expansion. He said Vibra Healthcare had implemented the platform across multiple care settings, and that the companies had demonstrated results and built an operational playbook they could replicate with health systems across the country.

What did Vibra Healthcare CEO Brad Hollinger say about the MindMaze Therapeutics partnership?

Brad Hollinger said Vibra Healthcare entered the relationship because it saw an opportunity to change what was possible in neurorehabilitation. He described the model built with MindMaze Therapeutics as scalable and said Vibra Healthcare intended to bring it to health system partners across the country.

What does MindMaze Therapeutics do?

MindMaze Therapeutics develops scalable precision neurotherapeutics by integrating software, proprietary sensors and AI-driven data analytics. Its products are designed to provide care from the acute hospital phase through outpatient treatment and home-based therapy, with applications including stroke, Parkinson’s disease and other neurological disorders.

Where are MindMaze Therapeutics shares listed and what is the ticker symbol?

MindMaze Therapeutics is identified in the announcement as listed on SIX under the ticker symbol MMTX.

What products and regulatory clearances does MindMaze Therapeutics have?

MindMaze Therapeutics says its products are FDA-cleared and CE-marked. The company describes them as scalable, reimbursable solutions intended to address the shortage of specialised clinicians.

What does Vibra Healthcare do?

Vibra Healthcare, LLC is a post-acute care provider based in Mechanicsburg, Pennsylvania, focused on developing, acquiring and operating freestanding specialty acute care hospitals, medical rehabilitation hospitals and outpatient physical rehabilitation centres. Its specialist teams run clinical programmes for patients with stroke, multiple traumas, major orthopaedic, neurologic, cardiac and respiratory conditions.

How large is Vibra Healthcare’s network?

Vibra Healthcare and its affiliates currently employ over 4,000 employees and own, operate and manage more than 25 specialty hospitals, transitional care facilities and hospital-based outpatient physical therapy locations across 10 states.

Home
News Intelligence
MindMaze Therapeutics Holding SA
MindMaze Therapeutics and Vibra Healthcare Sign U.S. Neurorehabilitation Partnership

Back to all MindMaze Therapeutics Holding SA press releases

MindMaze Therapeutics Holding SA

OTCQB:MMTZF
SIX:MMTX

MindMaze Therapeutics and Vibra Healthcare Sign U.S. Neurorehabilitation Partnership

Published Tuesday, 12 May 2026, 05:00 AM

Get alerts

Plain English summaries when MindMaze Therapeutics Holding SA announces news.

At a glance

Company: MindMaze Therapeutics Holding SA
Listings: OTCQB:MMTZF, SIX:MMTX
Announcement type: Corporate update
Published: Tuesday, 12 May 2026, 05:00 AM
Source announcement: eqs-news.com

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

MindMaze Therapeutics (SIX: MMTX) and Vibra Healthcare announced a definitive channel partnership agreement for U.S. health-system expansion.

The companies announced signing on May 12, 2026; Vibra will act as commercial partner for MindMaze's FDA-cleared digital neurotherapeutics platform.
The agreement follows a previously announced term sheet and formalizes Vibra's role connecting MindMaze with U.S. providers investing in neurorehabilitation capabilities.
The commercial model is anchored by Vibra's own two-year, multi-site deployment of MindMaze's platform across five inpatient rehabilitation centers.
MindMaze expects the partnership to drive new U.S. health-system customer acquisition in the second half of 2026 and beyond.

The deployment demonstrated that high-dose, high-intensity therapy recommended by guidelines could be operationalized at scale without increasing staffing burden.

Investor FAQs

MindMaze Therapeutics and Vibra Healthcare announced the signing of a definitive channel partnership agreement on May 12, 2026. The agreement formalises Vibra Healthcare’s role as a strategic commercial partner to introduce MindMaze Therapeutics’ FDA-cleared digital neurotherapeutics platform to leading U.S. health systems.

Source announcement

Company: MindMaze Therapeutics Holding SA
Title: MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S.
Published: Tuesday, 12 May 2026, 05:00 AM
Source site: eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…